Main Uses and Benefits of Supartz

Supartz is a hyaluronic acid-based injectable treatment designed to manage symptoms associated with osteoarthritis of the knee. It belongs to a class of therapies known as viscosupplementation, which aims to restore the natural properties of the joint fluid.

Therapeutic Applications

The primary use of Supartz is for the treatment of knee pain in patients who have not achieved an adequate response to conservative non-pharmacological therapies or simple analgesics. It is specifically utilized for individuals with osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage and changes in the synovial fluid.

In a healthy knee, synovial fluid contains high concentrations of hyaluronan, which provides lubrication and acts as a shock absorber. In patients with osteoarthritis, this fluid becomes thinner and less effective. Supartz is injected directly into the joint space to supplement this depleted fluid.

Expected Benefits

The goal of treatment with Supartz is to reduce joint discomfort and improve physical function. The benefits typically observed include:

• Pain Reduction: The primary benefit is the alleviation of chronic knee pain associated with movement and weight-bearing activities.
• Improved Mobility: By decreasing pain and improving joint lubrication, patients may experience an increased range of motion and a greater ability to perform daily activities such as walking or climbing stairs.
• Mechanical Support: The solution helps to lubricate the joint surfaces and absorb shock during physical impact, which may help protect the joint tissues from friction-related irritation.

While individual responses vary, the effects of the treatment are intended to provide relief over an extended period, potentially delaying the need for more invasive surgical interventions.

The eligibility for Supartz is strictly defined by regulatory labeling, which identifies both the approved patient population and conditions that absolutely prohibit its use.

Contraindications

Supartz must not be administered to patients under specific conditions:

• Patients with a known hypersensitivity (allergy) to sodium hyaluronate preparations.
• Patients with infections or skin diseases present in the area of the knee joint injection site.

---

Eligibility and Age Restrictions

• Allowed Population: Use is indicated for adult patients with osteoarthritis of the knee who have failed to respond adequately to non-pharmacologic therapy and simple analgesics.
• Pediatric Use: Safety and effectiveness have not been established in children.
• Pregnancy and Lactation: Safety and effectiveness have not been established in pregnant or nursing women, classifying its use as restricted in these groups.

---

Special Precautions

Caution is formally advised when injecting patients who are allergic to avian proteins, feathers, and egg products, a restriction related to the product's biological origin.

Interactions with other medicines and products

Official regulatory documentation for Supartz (sodium hyaluronate) primarily details interactions related to the administration procedure and local co-administration, reflecting its status as a non-systemic intra-articular agent. The product's interaction profile does not include systemic drug-drug interactions, as it is not metabolized through hepatic cytochrome P450 (CYP) enzymes or drug transporters.

Official Regulatory Interaction Statements

Interaction Type	Interacting Substance/Category	Official Restriction Statement
Chemical Incompatibility	Disinfectants containing Quaternary Ammonium Salts	These substances must not be used concomitantly for skin preparation, as the sodium hyaluronate solution is documented to precipitate in their presence.
Co-administration Restriction	Other Intra-articular Injectables	The safety and effectiveness of the use of Supartz concomitantly with other intra-articular injectables (such as local anesthetics or corticosteroids) have not been established by regulatory authorities.

This interaction structure is defined by the local, procedural constraints placed on the product. The prohibition of quaternary ammonium salts is a mandatory requirement to prevent a physical chemical reaction, while the restriction on other intra-articular agents indicates that official data on combined use are not available.

The mechanism of action for Sodium Hyaluronate involves a dual action comprising mechanical effects and cellular modulation, strictly localized to the intra-articular space.

Restoring Joint Fluid Dynamics through Viscosupplementation

This domain focuses on the physical mechanism where the injected high molecular weight Hyaluronate restores the synovial fluid's viscosity and elasticity. This action physically influences the articular cartilage surface by restoring rheological properties that mediate lubrication and load dissipation, which influences mechanical strain and friction within the joint.

Modulating Cellular Responses and Catabolic Pathways

The secondary action involves the molecule binding to receptors like CD44 on synoviocytes and chondrocytes, which modulates internal cellular signaling. This interaction helps to suppress the production of pro-inflammatory mediators (e.g., IL-1beta) and the activity of catabolic enzymes (e.g., MMPs). This biochemical effect results in the physiological consequence of attenuated localized inflammation and involves regulation of pathways associated with cartilage matrix degradation.

Attenuating Nociceptor Activity and Stimulating Endogenous Synthesis

The molecule further acts to physically shield and chemically modulate articular nociceptors (pain-sensing nerves), influencing the signal transduction frequency of these cells. Additionally, the mechanism includes stimulation of the native joint cells to increase their endogenous production of high-quality Hyaluronate, resulting in the modulation of the native joint homeostatic mechanisms that extend beyond the residence time of the exogenous product.

How to Use Supartz: Official Administration Guidelines

Supartz (sodium hyaluronate) is a medicine administered only via intra-articular injection—meaning directly into the joint space—and must be performed by or under the immediate supervision of a qualified physician. The use of this product is restricted to the knee joint, as its safety and effectiveness have not been established for other joints.

---

Dosing and Administration Schedule

Administration Scope	Official Labeled Instruction
Route	Intra-articular injection (into the knee joint)
Dose Volume	2.5 mL (containing 20 mg of sodium hyaluronate)
Frequency	Once a week (1 week apart)
Total Course	Five injections (The effectiveness of a course of less than five injections has not been fully established)
Bilateral Use	A separate syringe must be used for each knee if both joints are being treated
Age Group	Approved for use in adults

---

Mandatory Procedural Steps

Before administering Supartz, the physician must follow strict aseptic administration technique to prevent contamination. If there is excess fluid present in the joint (joint effusion), it must be removed before the injection is given. The full 2.5 mL contents of the syringe are to be injected into the single knee.

Following the procedure, patients are officially advised to restrict activity. For the 48 hours that immediately follow the intra-articular injection, the patient must avoid strenuous activities or activities that involve prolonged weight-bearing (i.e., standing for more than 1 hour), such as jogging or heavy lifting.

These official instructions define Supartz as a precise, medical-procedure-based treatment with a fixed schedule of five weekly injections, ensuring standardized use as required by government regulatory documents.

Supartz: Recent Clinical Evidence

Clinical evidence for Supartz (sodium hyaluronate) primarily focuses on its use as a viscosupplementation treatment for pain associated with osteoarthritis (OA) of the knee. Supartz is one of several hyaluronic acid (HA) products used in intra-articular injections.

---

Pivotal Clinical Trials and Outcomes

Regulatory approval for Supartz was supported by data from multiple randomized controlled trials (RCTs) comparing the product to a saline placebo. These studies, involving adult patients, investigated changes in pain and function using standardized indices such as the Visual Analogue Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

• Research findings have consistently shown that five weekly injections of Supartz into the knee joint may be associated with reductions in pain and improvements in joint function for up to six months when compared to baseline scores.
• Safety profiles assessed in these pivotal trials indicated that the incidence of adverse events, such as arthralgia or injection site reactions, was generally similar between the Supartz group and the saline control group.

---

Comparative and Advanced Research

More recent non-inferiority trials have evaluated Supartz against other commercially available hyaluronic acid preparations. These studies explore whether Supartz performs similarly to other HA products in relieving knee OA pain.

Preclinical research has explored the mechanism by which injected hyaluronic acid may affect the joint environment. These investigations suggest potential pathways involving an increase in the viscoelasticity of the synovial fluid, anti-inflammatory activity, and interaction with cellular receptors that may support joint health. The clinical relevance of these laboratory findings in humans continues to be a focus of ongoing study.

Common questions about Supartz (FAQ)

Q: How does Supartz differ from other knee injections like Euflexxa or Synvisc?

A: Official documents describe Supartz as a high molecular weight sodium hyaluronate product, with a specific molecular weight range. A key differentiating fact is that the sodium hyaluronate in Supartz is sourced from chicken combs, confirming its biological origin.

Q: How long does it typically take to notice the effects of Supartz after the injection?

A: Clinical information indicates that the full therapeutic benefit may begin to be noticed after the second or third injection in the total five-injection series. For those who experience relief, improvements may become apparent within several weeks of starting the full treatment course.

Q: Is it common to feel stiffness in the knee after a Supartz shot?

A: Yes, regulatory documents list stiffness, along with warmth, pain, and swelling at the injection site, as common adverse reactions that may occur immediately following the injection. These local reactions are typically temporary.

Q: Does Supartz interact with common over-the-counter pain medications?

A: Official regulatory documents describe Supartz as a non-systemic agent. This means it is not metabolized through the body's main enzyme systems and therefore has no known systemic drug-drug interactions with most oral medications, including common over-the-counter pain relievers.

Q: How soon after a Supartz injection can a person drive or return to work?

A: Official patient information specifies a 48-hour restriction immediately following the injection. During this time, the patient must avoid strenuous activities and activities that involve prolonged weight-bearing, though the document does not specify general activities like driving or light office work.

Q: What should be done if swelling occurs at the injection site a few days later?

A: While mild swelling at the injection site is a common and usually temporary side effect, official warnings state that a doctor should be contacted immediately if severe pain or severe swelling occurs around the knee after the injection.

Q: Is it true that Supartz injections replace the natural fluid in the knee?

A: No, Supartz does not replace the natural fluid. It is classified as a viscosupplementation agent which works by supplementing and restoring the natural viscoelastic properties of the fluid already present in the knee joint.

Q: Can Supartz injections cause temporary worsening of arthritis symptoms?

A: Yes, official safety information indicates that a temporary increase in joint pain is listed as a common adverse event that may occur shortly after the injection is administered.

Q: What is the difference between a high-molecular-weight and low-molecular-weight hyaluronic acid product like Supartz?

A: Regulatory labeling defines Supartz as a high molecular weight sodium hyaluronate product, which is a key technical characteristic. This high molecular weight is intended to help restore the fluid's ability to act as a lubricant and shock absorber within the joint.

Q: Is the term 'viscosupplementation' the same as using a lubricant in the knee?

A: The official term 'viscosupplementation' refers to the medical process of injecting a substance like Supartz to supplement the joint fluid. This action is described in patient-facing regulatory materials as helping the fluid restore properties that allow it to act as a lubricant and cushion.

Q: What if the doctor does not remove excess fluid (joint effusion) before the injection?

A: Official administration instructions state that any excess fluid (known as joint effusion) present in the joint is to be removed by the physician before the injection of Supartz is given. This instruction ensures the proper administration of the product.

Q: Is there a limit to the number of times a person can receive Supartz injections?

A: Clinical evidence has examined the use of repeated courses of Supartz injections. These courses are generally spaced after a period of approximately six months, if a patient received significant benefit from the initial course.

Q: Can Supartz be given while a patient is taking blood thinners?

A: The official product information does not list blood thinners as a specific contraindication or interaction. However, because the procedure involves an intra-articular injection, regulatory principles dictate that any medications affecting bleeding should be discussed with the administering physician.

Q: Are there any known drug interactions with common supplements like glucosamine or turmeric?

A: Regulatory documents state that Supartz is a non-systemic agent that has no known systemic drug-drug interactions. This means it is generally not expected to interact with the metabolism of most oral supplements like glucosamine or turmeric.

Q: Does the manufacturing process for Supartz follow any specific safety standards?

A: Yes, Supartz is classified by the U.S. Food and Drug Administration (FDA) as a Class III medical device. This classification requires the product's manufacturing process to adhere to specific, rigorous quality control and safety standards defined by the federal agency.

Q: Why is Supartz administered as a series of injections rather than a single dose?

A: The full course of five weekly injections is the officially established regimen because regulatory studies have not established the effectiveness of a treatment cycle consisting of fewer than five total injections.

Q: Does Supartz contain any preservatives or latex?

A: The official ingredient list for the solution includes the active ingredient, sodium hyaluronate, dissolved in a physiological buffer containing sodium chloride and phosphates, with water for injection. Preservatives are not listed in the provided ingredients.

Q: What is the purpose of the liquid component in the Supartz injection?

A: The active ingredient, sodium hyaluronate, is dissolved in a physiological saline solution. This saline solution acts as the sterile, inactive carrier or vehicle that allows the active ingredient to be properly administered into the knee joint.

Q: How long has Supartz been available for patient use?

A: Supartz has been available for patient use in the United States since its initial regulatory clearance by the U.S. Food and Drug Administration (FDA) in 2001.

The official labeling for Supartz (sodium hyaluronate) specifies strict conditions to maintain the sterility and stability of the product.

Storage Requirements

Supartz must be stored at a controlled temperature below 77 F (25 C) and is explicitly required to NOT FREEZE. The product must remain in its original, undamaged packaging until the time of use. Adherence to these conditions supports the labeled shelf life of 42 months.

Disposal Instructions

The prefilled syringe is intended for single use only. The contents must be used immediately once the container is opened, and any unused portion, along with the syringe, must be discarded. The regulatory mandate is that the syringe shall not be re-used. Disposal of the medical waste must follow all local, state, and federal regulations.